We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » STUDY: COMBINED THERAPY IMPROVES HEART FAILURE TREATMENT

STUDY: COMBINED THERAPY IMPROVES HEART FAILURE TREATMENT

May 12, 2006

Patients face a reduced risk of cardiovascular death and heart failure hospitalizations when an Angiotensin-converting Enzyme (ACE) inhibitor is combined with use of AstraZeneca's drug Atacand, a study published in the May issue of the American Heart Journal finds.

An AstraZeneca-sponsored study found that treatment was significantly more effective when Atacand (candesartan cilexetil) was combined with the ACE inhibitor than when the inhibitor was used alone. ATACAND is the only angiotensin II receptor blocker indicated to provide these clinical benefits for heart failure patients already receiving adequate doses of an ACE inhibitor, the company says.

Specifically, the Candesartan in Heart failure: Assessment of Reduction in Mortality and Morbidity (CHARM)-Added trial concluded that the drug reduced the relative risk for the primary end point of cardiovascular death or heart failure hospitalization significantly compared to placebo (hazard ratio (HR) 0.85, 95% confidence intervals (CI) 0.75-0.96, p=0.011). This outcome was consistent in patients taking a guideline-recommended ACE inhibitor dose and for those taking an FDA-designated maximum ACE inhibitor dose, (HR) 0.79, 95% CI 0.67-0.95; HR 0.75, 95% CI 0.57-0.98, respectively).

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • Thermo Fisher Scientific Gets FDA Premarket Approval for Companion Diagnostic

  • MHRA Grants Conditional Authorization to Moderna’s Bivalent COVID-19 Booster Vaccine

  • Organogenesis Gets 510(k) Clearance to Expand PuraPly Portfolio

  • FDA Grants Priority Review to sNDA for Lynparza

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing